Format

Send to

Choose Destination
Prog Brain Res. 2017;231:87-105. doi: 10.1016/bs.pbr.2016.10.001. Epub 2017 Jan 2.

Rebuilding CNS inhibitory circuits to control chronic neuropathic pain and itch.

Author information

1
University of California-San Francisco, San Francisco, CA, United States.
2
Cardiovascular Medicine, Human Physiology and Centre for Neuroscience, Flinders University, Bedford Park, SA, Australia.
3
University of California-San Francisco, San Francisco, CA, United States. Electronic address: allan.basbaum@ucsf.edu.

Abstract

Cell transplantation offers an attractive alternative to pharmacotherapy for the management of a host of clinical conditions. Most importantly, the transplanted cells provide a continuous, local delivery of therapeutic compounds, which avoids many of the adverse side effects associated with systemically administered drugs. Here, we describe the broad therapeutic utility of transplanting precursors of cortical inhibitory interneurons derived from the embryonic medial ganglionic eminence (MGE), in a variety of chronic pain and itch models in the mouse. Despite the cortical environment in which the MGE cells normally develop, these cells survive transplantation and will even integrate into the circuitry of an adult host spinal cord. When transplanted into the spinal cord, the cells significantly reduce the hyperexcitability that characterizes both chronic neuropathic pain and itch conditions. This MGE cell-based strategy differs considerably from traditional pharmacological treatments as the approach is potentially disease modifying (i.e., the therapy targets the underlying etiology of the pain and itch pathophysiology).

KEYWORDS:

Cell transplant; Dorsal horn; GABA; Itch; Medial ganglionic eminence; Pain; Spinal cord

PMID:
28554402
DOI:
10.1016/bs.pbr.2016.10.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center